Our Third Eye® Panoramic™ device has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) and is now being used nationwide.
Avantis has an extensive portfolio of patents covering innovative devices based on the convergent technologies of micro-chips and enhanced video processing systems. To date, the Company has 13 issued patents and 13 patents pending. The Company has pending patent applications in the U.S. and international markets specifically directed to core Third Eye technologies, as well as a foundational issued patent in Japan.
The heart of the Third Eye Panoramic system is the Third Eye Video Processor, which serves as a digital hub (“dHub”) for the technology.
Avantis is extending the capabilities of the dHub. The company is developing new software technology called Automated Polyp Detection (APD) that utilizes machine learning (ML) to assist the physician in identifying suspicious areas that deserve further examination. While currently for investigational use only, these advanced software tools could be instrumental for improved cancer screening and over time will provide the potential for automated detection of polyps, cancers and other abnormalities.